Recently listed Biopharmaceutical company Exopharm Limited (ASX: EX1) released the investor’s deck to provide high-level information on the company’s business and its development programs.
The company focuses on providing the health-span solution through a cell-free approach under which patients are dosed with a boost of exosomes purified from adult stem cells or derived from human platelets. In this process, a count of exosomes increases in the body that results in an improvement in health span.
Exopharm explained the young and healing health depends upon the number of exosomes present in the human body. The studies have proven that as the person moves towards aging, fewer good exosomes are found in its body whereas more regenerative exosomes exist in a youthful body.
With the development and commercialization of exosomes as the therapeutic agents, the company aims to become leading human clinical therapeutics using exosomes as regenerative medicine products. In the process of exosomes purification, the company uses its manufacturing technology called LEAP in comparison to the generally used ultracentrifuge [UC] process.
It delivers two exosomes products: Plexaris™, the technology in which exosomes are derived from platelets, and Exomeres™ in which exosomes are purified from adult cells using LEAP technology.
On the financial front, the company posted the loss of $174,597 for the year ended 30 June 2018. It includes research and development expenses of $79,164 and corporate expense of $66,908 among other costs and charges. As at 30 June 2018, cash and cash equivalents of the company were $52,401.
Exopharm got listed on Australian Securities Exchange under the code EX1 on 18 December 2018. In its initial public offering, it raised A$7 million on the issue of 80.5 million shares out of which approximately 28 million shares were held by Dr. Ian Dixon, founding director of Exopharm Limited. Currently, Dr. Dixon holds around 34.70% of total Exopharm’s holding through its private company Altnia Holdings Pty Ltd.
The company targets to introduce its first-in-human study of Plexaris by the mid-calendar year 2019. Further, it aims to increase investments in a development program to attract a following pharmaceutical company transaction and partnerships potentially.
In today’s trading session, Exopharm shares have nosedived 12.281% to trade at $0.500 as at 28 December 2018 (1:49 PM AEST). However, in the past 5-day trade, the stock has jumped up by 32.56%.
Based is in Melbourne, Australia, the company changed its name from Exopharm Pty Ltd to Exopharm Limited in August 2018. As at 28 December 2018, its market capitalization is $45.88 million.